You Lü
Tulane University(US)University of Nottingham Ningbo China(CN)Donghua University(CN)Shanghai Jiao Tong University(CN)Hebei University of Technology(CN)University of New Orleans(US)Chengdu Medical College(CN)Sichuan University(CN)Wenzhou Medical University(CN)Ruijin Hospital(CN)Shanghai Chest Hospital(CN)West China Second University Hospital of Sichuan University(CN)West China Hospital of Sichuan University(CN)Sichuan Cancer Hospital(CN)Shanghai Electric (China)(CN)Jiangsu Cancer Hospital(CN)Affiliated Hospital of Youjiang Medical University for Nationalities(CN)Shanghai Tenth People's Hospital(CN)Huashan Hospital(CN)State Key Laboratory of BiotherapyHuazhong University of Science and Technology(CN)Nanjing Medical University(CN)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Lung Cancer Diagnosis and Treatment, Lung Cancer Research Studies, Cancer Immunotherapy and Biomarkers, Colorectal Cancer Treatments and Studies
Most-Cited Works
- → Clades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues(2004)1,053 cited
- → Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer(2020)516 cited
- → Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial(2015)405 cited
- → BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung Cancer(2015)387 cited
- → Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)(2020)381 cited